Our global
team

The CRISPR patent portfolio licensed via ERS (known as the CVC portfolio) is the most comprehensive collection of proprietary rights to the fundamental CRISPR/Cas9 gene editing platform. Built on the Nobel Prize winning work of Emmanuelle Charpentier and Jennifer Doudna, ERS grants non-exclusive licenses to a growing list of issued and pending patent applications globally, in all fields excluding direct use as a human therapeutic.

Founders

Dr. Emmanuelle Charpentier
Dr. Emmanuelle Charpentier

Scientific advisor &
Co-Founder
Dr. Roger Novak

Member of the Board of
Directors & Co-Founder

Shaun Foy

Chairman of the Board of
Directors & Co-Founder

Team

Eric Rhodes


CEO
Michael Arciero, JD

Michael Arciero, JD

Vice President IP &
Commercial Development

Jon Kratochvil
Jon Kratochvil

Vice President Business Development
& Licensing for North America
Dan Carey
Dan Carey

Sr. Director, Business
Development & Licensing
FangFang (JoJo) Hu
FangFang (JoJo) Hu


China Business Director

Tracy McGann


Head of Finance

Dara O’Donnell


Marketing Director
John Ireland


Business Analyst
Janice Valentine
Janice Valentine


Executive Assistant